Shares

6 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 13, 2024

BUY
$171.37 - $283.23 $18.9 Million - $31.3 Million
110,507 New
110,507 $29.5 Million
Q3 2019

Nov 14, 2019

SELL
$84.4 - $106.53 $2.95 Million - $3.73 Million
-35,000 Closed
0 $0
Q1 2019

May 10, 2019

SELL
$103.48 - $143.84 $3.62 Million - $5.03 Million
-35,000 Reduced 50.0%
35,000 $4.38 Million
Q4 2018

Feb 11, 2019

BUY
$94.77 - $215.54 $1.9 Million - $4.31 Million
20,000 Added 40.0%
70,000 $7.89 Million
Q2 2018

Aug 10, 2018

BUY
$101.55 - $313.9 $507,750 - $1.57 Million
5,000 Added 11.11%
50,000 $14 Million
Q1 2018

May 10, 2018

BUY
$93.35 - $149.04 $4.2 Million - $6.71 Million
45,000 New
45,000 $5.26 Million

Others Institutions Holding MDGL

About MADRIGAL PHARMACEUTICALS, INC.


  • Ticker MDGL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 17,103,400
  • Market Cap $5.52B
  • Description
  • Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Its lead product candidate is resmetirom, a liver-directed selective thyroid hormone receptor-ß agonist, which is in Phase III c...
More about MDGL
Track This Portfolio

Track Artal Group S.A. Portfolio

Follow Artal Group S.A. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Artal Group S.A., based on Form 13F filings with the SEC.

News

Stay updated on Artal Group S.A. with notifications on news.